Invivyd (IVVD) Expected to Announce Quarterly Earnings on Thursday

Invivyd (NASDAQ:IVVD - Get Free Report) is projected to release its Q4 2024 earnings data before the market opens on Thursday, March 20th. Analysts expect Invivyd to post earnings of ($0.25) per share and revenue of $13.57 million for the quarter.

Invivyd (NASDAQ:IVVD - Get Free Report) last released its quarterly earnings results on Thursday, March 20th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.10. The company had revenue of $13.80 million for the quarter, compared to analysts' expectations of $13.57 million. On average, analysts expect Invivyd to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Invivyd Stock Performance

NASDAQ IVVD traded down $0.00 on Friday, hitting $0.74. 2,780,420 shares of the stock were exchanged, compared to its average volume of 4,239,301. Invivyd has a 52-week low of $0.35 and a 52-week high of $4.74. The firm has a market capitalization of $88.28 million, a P/E ratio of -0.38 and a beta of 0.09. The stock has a fifty day moving average price of $0.98 and a two-hundred day moving average price of $0.87.

Insider Buying and Selling at Invivyd

In related news, Director Terrance Mcguire sold 83,817 shares of the company's stock in a transaction on Thursday, December 26th. The stock was sold at an average price of $0.54, for a total value of $45,261.18. Following the transaction, the director now directly owns 3,340,520 shares of the company's stock, valued at $1,803,880.80. This represents a 2.45 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last ninety days, insiders sold 246,138 shares of company stock worth $120,902. 17.90% of the stock is owned by insiders.

Remove Ads

Analysts Set New Price Targets

Several research firms have issued reports on IVVD. D. Boral Capital reissued a "buy" rating and issued a $9.00 price objective on shares of Invivyd in a research report on Thursday. HC Wainwright restated a "buy" rating and set a $10.00 price objective on shares of Invivyd in a report on Monday, February 24th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $7.89.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.